Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers related to the long-term safety of JAK inhibitors compared to TNF inhibitors. In our first paper, Christina Charles-Schoeman and colleagues assessed the risk of venous thromboembolism in patients with RA initiating tofacitinib or TNFi. Our second paper is from Roy Fleischmann and colleagues compare the long-term efficacy and safety data of upadacitinib switched from adalimumab and in adalimumab s ..read more

Join Professor Peter Nash from the Griffith University in Brisbane, and Maria Antonietta D’Agostino, the Head of the Rheumatology Department at the Catholic University of the Sacred Heart in Rome, as they discuss her recent paper 'Effects of Secukinumab on Synovitis and Enthesitis in Patients with Psoriatic Arthritis: 52-week Clinical and Ultrasound Results from the Randomised, Double-blind ULTIMATE Trial with Open Label Extension ..read more

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Dennis McGonagle, a Clinical Professor at the University of Leeds School of Medicine, as they discuss his recent paper ‘Association of the Clinical Components in the Distal Interphalangeal Joint Synovio-entheseal Complex and Subsequent Response to Ixekizumab or Adalimumab in Psoriatic Arthritis ..read more

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvements is sacroiliac joint symptoms across patients with AS and axSpA treated with different DMARDs ..read more

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jürgen Rech, a Senior Physician at the Friedrich-Alexander University of Erlangen-Nürnberg, as they discuss his recent paper ‘Abatacept Inhibits Inflammation and Onset of Rheumatoid Arthritis in Individuals at High Risk (ARIAA): A Randomised, International, Multicentre, Double-blind, Placebo-controlled Trial ..read more

Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the long-term safety of ixekizumab as well as bimekizumab treatment in a TNFi-IR population ..read more

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that that add to the knowledge of common treatments relating to RA. In our first paper, Juergen Rech and colleagues present the results of the ARIAA study, which shows that abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. Our second paper is from Juergen Rech and colleagues, where they present the results of the ARIAA study which investigated whether ..read more

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs) and 24-month retention rates between patients with axSpA and PsA that were treated with secukinumab ..read more

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that show the long-term safety and efficacy of JAK inhibitors, both of which have a study period of 6.5 years. In our first paper, Roberto Caporali and colleagues show long-term safety and efficacy data for baricitinib as an RA therapy. Our second paper is from Christina Charles-Schoeman and her colleagues, where they present long-term data on the effect of upadacitinib on laboratory pa ..read more

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Mahta Mortezavi, a Clinical Director for Drug Discovery and Early Development as part of the Anti-infectives Research Unit at Pfizer, as they discuss her recent paper ‘Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumour necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance ..read more